The MESO-CAR T cell therapy is positioned to address a significant unmet need in relapsed and refractory ovarian cancer, particularly for patients expressing mesothelin. Given the limited treatment options for this patient population, successful outcomes could establish a competitive advantage in the CAR-T therapy landscape. The collaboration with Hrain Biotechnology Co., Ltd. may enhance development capabilities and commercialization strategies. The market for ovarian cancer therapies is growing, with increasing focus on personalized medicine and immunotherapies, indicating potential for substantial market capture if the therapy demonstrates efficacy and safety.